Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 12/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.37 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.37 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.37 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29954668 | 0.86 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2878161 | 0.86 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2873485 | 0.85 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL2926879 | 0.84 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL16249235 | 0.83 | NR1H2 (0.42) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL24076657 | 0.82 | NR1H2 (0.41) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL759757 | 0.81 | NR1H2 (0.40) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL19645304 | 0.81 | GABRG2 (0.38) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL12422263 | 0.81 | GABRG2 (0.38) | NR1H2CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL12011423 | 0.81 | NR1H2 (0.37) | NR1H2CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2791120-B1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2016-02-24 | — | — | EP | disclosed |
| US-9115121-B2 | 1,3,5-triazine-2-amine derivatives, preparation thereof and diagnostic and therapeutic use thereof | SANOFI (FR) | 2015-08-25 | — | — | US | disclosed |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | SANOFI (FR) | 2014-11-20 | — | — | US | disclosed |
| EP-2791120-A1 | 1,3,5 -TRIAZINE-2-AMINE DERIVATIVES, PREPARATION THEREOF AND DIAGNOSTIC AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-10-22 | — | — | EP | disclosed |
| EP-2325186-B1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS LLC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-8796455-B2 | Fused bicyclic mTOR inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-08-05 | — | — | US | disclosed |
| US-8586546-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-11-19 | — | — | US | disclosed |
| EP-2385053-B1 | Intermediates for the preparation of fused bicyclic mTOR inhibitors | OSI PHARM INC (US) | 2013-10-02 | — | — | EP | disclosed |
| US-7700594-B2 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-7651687-B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090274698-A1 | Combination anti-cancer therapy | OSI PHARMACEUTICALS, INC. | 2009-11-05 | — | — | US | disclosed |
| CN-101495449-A | 2-phenyl-indoles as prostaglandin D2 receptor antagonists | SANOFI AVENTIS (FR) | 2009-07-29 | — | — | CN | disclosed |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-07-09 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| EP-2066628-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | Sanofi-Aventis (FR) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008014186-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2008-01-31 | — | — | WO | disclosed |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | OSI PHARMACEUTICALS, INC. | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | NR1H2 3002/4885CHRM2 4883/4885CHRM4 4882/4885 |
| US-20090274698-A1 | Combination anti-cancer therapy | MTOR, RICTOR, AKT1 | NR1H2 4282/4885CHRM2 4835/4885CHRM4 4880/4885 |
| US-20140343061-A1 | 1,3,5 -Triazine-2-Amine Derivatives, Preparation Thereof And Diagnostic And Therapeutic Use Thereof | ALK, HRH3, HRH4 | NR1H2 2088/4885CHRM2 135/4885CHRM4 498/4885 |
| US-20070280928-A1 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | EGFR, ERBB2, RICTOR | NR1H2 1750/4885CHRM2 4289/4885CHRM4 4117/4885 |
| US-20070112005-A1 | mammalian Target Of Rapamycin (mTOR) kinase; for treatment of lymphoma or ovarian cancer | MTOR, MAPKAP1, RPS6KA1 | NR1H2 1606/4885CHRM2 4881/4885CHRM4 4876/4885 |
| US-20090176804-A1 | 2-PHENYL-INDOLES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGER2, PTGDR2, CYSLTR2 | NR1H2 212/4885CHRM2 87/4885CHRM4 869/4885 |
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | HTR5A, HTR2C, TPH1 | NR1H2 1642/4885CHRM2 1436/4885CHRM4 1043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.